Clinical

Dr Ian Riddock explains the patient journey post-myocardial infarction (MI), from hospital to outpatient care.

Ian Riddock, MD, discusses the burden of atherosclerotic cardiovascular disease (ASCVD) and multi-societal guideline recommendations for lipid management.

Recent clinical trials have excluded older patients with eosinophilic esophagitis (EoE) from participating; however, patients aged 65 years and older are more likely to respond to topical corticosteroids than their younger counterparts.

The clinical utility of genomic profiling was demonstrated in patients with advanced gastrointestinal (GI) cancers whose access to targeted therapies based on tissue-based assay findings was similar to those with non-GI cancers.

A trastuzumab biosimilar was found to have similar safety and efficacy with the reference product (Herceptin) in patients with advanced gastric cancer, a population previously excluded from bioequivalence studies for trastuzumab biosimilars.

A retrospective study found that chronic obstructive pulmonary disease (COPD) was associated with postoperative pulmonary complications and longer length of stay (LOS) following lung cancer resection.

Analyses of blood-based markers showed an association between diabetes and higher glycated hemoglobin with cognitive impairment among those with Parkinson disease.

Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.

Experts in behavioral health discuss therapeutic options for TRD and considerations for defining value.

The acceleration of science and medicine is exciting, but these new advances are not always moving into practice, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital, and associate professor of medicine at Harvard Medical School.

Jay Weaver, PharmD, MPH, and Muhamed Baljević, MD, FACP, discuss how RWE can affect the management of MM.

Dr Richter relays some of the differences between real-world evidence (RWE) and RCT data, as well as how they can work together when determining therapy.

In this case, a patient died 18 months following his transplant after developing de novo intrahepatic cholangiocarcinoma.

Patients often have comorbidities that make it important to consider them holistically and not bucket them into one disease state, and the findings on rivaroxaban show broad benefits and a favorable risk-benefit profile, said Marc Bonaca, MD, MPH, of CPC Clinical Research and CPC Community Health and the University of Colorado School of Medicine.

Treating children with familial hypercholesterolemia (FH) early can help reduce progression of atherosclerosis without adverse events related to growth and development, said Raul Santos, MD, PhD, director, Lipid Clinic at the Heart Institute, and associate professor, University of São Paulo Medical School, Brazil.

Immune checkpoint inhibitors have changed the treatment landscape of certain cancer types, and a recent study aims to provide new insight on why treatment response varies so much from patient to patient.

Of 5 RNA investigated, 2 correlated with systemic lupus erythematosus and the last correlated with certain inflammation-related symptoms.

There is some confusion about the differences between the European and American guidelines on lowering low-density lipoprotein (LDL) cholesterol, but it’s clear that lower is better, said Pam Taub, MD, FACC, professor of medicine, Division of Cardiovascular Medicine, UC San Diego School of Medicine.

Because type 1 diabetes can be very difficult to effectively manage in children and adolescents, these study investigators compared outcomes between a hybrid closed-loop algorithm add-on and usual care.

Additional analyses from the SCORED trial further highlight sotagliflozin's benefits among patients with type 2 diabetes and chronic kidney disease, regardless of cardiovascular disease presence.

Milind Desai, MD, MBA, director of the Center for Hypertrophic Cardiomyopathy and medical director of the Center for Aortic Diseases, Cleveland Clinic, speaks on therapeutic implications of the VALOR-HCM late-breaking clinical trial findings presented Saturday at the American College of Cardiology's 71st Scientific Session.

The clinical effectiveness of chimeric antigen receptor (CAR) T-cell therapies adds a new weapon in the arsenal to treat patients with relapsed and refractory disease; however, they come with access, logistical, and reimbursement challenges that make it difficult to treat all the patients who could benefit.

Both fidaxomicin and vancomycin are recommended for treatment of Clostridioides difficile infections, but real-world data suggest fidaxomicin should be the go-to treatment option.

A recent report details the first reported case of an osteolytic lesion in polycythemia vera and reviews current literature on osteolytic lesions in myeloproliferative neoplasms (MPNs) overall.

A recent review highlighted the benefits of conducting further research on surgical disease modification to slow the progression of Parkinson disease.